Emerging drugs for postoperative ileus

Expert Opinion on Emerging Drugs

Volumn 12, Issue 4, 2007, Pages 619-626

  Greenwood Van Meerveld, Beverley ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Colon; Gastrointestinal transit; Ileus; Motility; Postoperative; Small intestine; Stomach; Surgery

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; CISAPRIDE; ERYTHROMYCIN; GSK 326416; IPAMORELIN; KOS 2187; LUBIPROSTONE; MD 01100; METOCLOPRAMIDE; MITEMCINAL; NEOSTIGMINE; NEPADUTANT; OPIATE ANTAGONIST; PLACEBO; TZP 101; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; BLOATING; BRADYCARDIA; CLINICAL TRIAL; COLON; CONSTIPATION; DEFECATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRACT FUNCTION; HEALTH CARE COST; HEART ARRHYTHMIA; HOSPITALIZATION; HUMAN; ILEUS; LOW DRUG DOSE; MORBIDITY; NONHUMAN; NORADRENERGIC SYSTEM; POSTOPERATIVE PERIOD; REVIEW; STOMACH EMPTYING; STOMACH PARESIS; TREATMENT OUTCOME; VOMITING;

EID: 36549063027     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.12.4.619     Document Type: Review

References (73)

1. WOODS MS: Postoperative ileus: dogma versus data from bench to bedside. Prospect. Colon. Rectal. Surg. (2000) 12:57-76.
2. KEHLET H, WILLIAMSON R, BUCHLER MW, BEART RW: A survey of perceptions and attitudes among European surgeons towards the clinical impact and management of postoperative ileus. Colorectal Dis. (2005) 7:245-250.
3. SENAGORE AJ: Overview of POI and its impact on surgical outcomes. Contemp. Surg. (2006):4-7.
4. ARTINYAN A, NUNOO-MENSAH JW, ESSANI R et al.: Prolonged postoperative ileus: definition, risk factors and predictors in patients undergoing open colorectal surgery. Gastroenterology (2005) 128:A-979.
5. GREENWOOD-VAN MEERVELD B, GARDNER CJ, LITTLE PJ et al.: Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol. Motil. (2004) 16:46-53.
6. BAUER AJ, BOECKXSTAENS GE: Postoperative ileus. Neurogastroenterol. Motil. (2004) 16:54-60. •• This is a general overview that describes, in detail, the mechanisms of POI.
7. SAGRADA A, FARGEAS MJ, BUENO L: Involvement of α1- and α2-adrenoceptors in the postlaparotomy intestinal motor disturbances in the rat. Gut (1987) 28:955-959.
8. BOECKXSTAENS GE, HIRSCH DP, KODDE A et al.: Activation of an adrenergic and vagally mediated NANC pathway in surgery-induced fundic relaxation in the rat. Neurogastroenterol. Motil. (1999) 11:467-74.
9. HOLZER P, LIPPE IT, AMMANN R: Participation of capsaicin-sensitive afferent neurons in gastric motor inhibition caused by laporatomy and intraperitoneal acid. Neuroscience (1992) 48:715-722.
10. BARQUIST E, BONAZ B, MARTINEZ V et al.: Neuronal pathways involved in abdominal surgery-induced gastric ileus in rats. Am. J. Physiol. (1996) 270: R888-R894.
11. BONAZ B, TACHE Y: Corticotrophin-releasing factor and systemic capsaicin - sensitive afferents are involved in abdominal surgery-induced Fos expression in the paraventricular nucleus of the hypothalamus. Brain Res. (1997) 748:12-20.
12. TACHE Y, MONNIKES H, BONAZ B, RIVIER J: Role of CRF on stress-related alterations of gastric and colonic motor function. Ann. NY Acad. Sci. (1993) 697:233-243.
13. DE WINTER BY, BOECKXSTAENS GE, DE MAN JG et al.: Effect of adrenergic and nitrergic blockade on experimental ileus in rats. Br. J. Pharmacol. (1997) 120:464-468.
14. DE WINTER BY, ROBBEREECHT P, BOECKXSTAENS GE et al.: Role of VIP1/PACAP receptors in post-operative ileus in rats. Br. J. Pharmacol. (1998) 124:1181-1186.
15. BOECKXSTAENS GE, HOLLMANN M, HEISTERKAMP SH et al.: Evidence for VIP (1)/PACAP receptors in the afferent pathway mediating surgery-induced fundic relaxation in the rat. Br. J. Pharmacol. (2000) 131:705-710.
16. KÄLFF JC, TÜRLER A, SCHWARZ NT, SCHRAUT WH et al.: Intra-abdominal activation of a local inflammatory response within the human muscularis externa during laparotomy. Ann. Surg. (2003) 237:301-315.
17. SCHWARZ NT, BEER-STOLZ D, SIMMONS RL et al.: Pathogenesis of paralytic ileus: intestinal manipulation opens a transient pathway between the intestinal lumen and the leukocytic infiltrate of the jejunal muscularis. Ann. Surg. (2002) 235:31-40.
18. DE JONGE WJ, THE FO, VAN DER ZANDEN EP et al.: Inflammation and gut motility: neural control of intestinal immune cell activation. J. Pediatr. Gastroenterol. Nutr. (2005) 41:S10-S11.
19. KÄLFF JC, CARLOS TM, SCHRAUT WH et al.: Surgically induced leukocytic infiltrates within the rats intestinal muscularis mediate postoperative ileus. Gastroenterology (1999) 117:378-387. • This paper describes for the reader an animal model of POI and the role of inflammation in the development of POI.
20. THE FO, DEJONGE WJ, BENNINK RK et al.: The ICAM-1 antisense oligonucleotide ISIS-3082 prevents the development of postoperative ileus in mice. Br. J. Pharmacol. (2005) 146:252-258
21. KÄLFF JC, ESKANDARI MK, HIERHOLZER C et al.: Biphasic response to gut manipulation and temporal correlation of cellular infiltrates and muscle dysfunction in rats. Surgery (1999) 126:498-509.
22. TURLER A, MOORE BA, PEZZONE MA et al.: Colonic postoperative inflammatory ileus in the rat. Ann. Surg. (2002) 236:56-66.
23. KREISS C, TOEGEL S, BAUER AJ: α2 adrenergic regulation of NO production alters postoperative intestinal smooth muscle dysfunction in rodent. Am. J. Physiol. (2004) 287:G658-G666. •• This is a key paper describing the potential link between the immune system and CNS in the development of POI.
24. LIGHTFOOT AJ, ENO M, KREDER KJ et al.: Treatment of postoperative ileus after bowel surgery with low-dose intravenous erythromycin. Urology (2007) 69:611-615.
25. KURZ A, SESSLER D: Opioid-induced bowel dysfunction. Pathophysiology and potential new therapies. Drugs (2003) 63:649-671.
26. BROWN DR: The use and misuse of quaternary ammonium opiate antagonists. Trends Pharmacol. Sci. (1985) 6:394-395.
27. BROWN DR, GOLDBERG LI: The use of quaternary narcotic antagonists in opiate research. Neuropharmacology (1985) 24:181-191.
28. BROWN DR, ROBERTSON MJ, GOLDBERG LI: Reversal of morphine-induced catalepsy in the rat by narcotic antagonists and their quaternary derivatives. Neuropharmacol. (1983) 22:317-321.
29. FOSS JF: A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am. J. Surg. (2001) 182:S19-S26.
30. GMEREK DE, COWAN A, WOODS JH: Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats. J. Pharmacol. Exp. Ther. (1986) 236:8-13.
31. KOTAKE AN, KUWAHARA SK, BURTON E et al.: Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans. Xenobiotica (1989) 19:1247-1254.
32. LOCKE KW, HOLTZMAN SG: Characterization of the discriminative stimulus effects of centrally administered morphine in the rat. Psychopharmacology (1985) 87:1-6.
33. MICKLEY GA, STEVENS KE, GALBRAITH JA: Quaternary naltrexone reverses morphine-induced behaviors. Physiol. Behav. (1985) 35:249-253.
34. RUSSELL J, BASS P, GOLDBERG LI et al.: Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur. J. Pharmacol. (1982) 78:255-261.
35. YUAN C-S, FOSS JF: Methylnaltrexone: investigation of clinical applications. Drug Dev. Res. (2000) 50:133-141.
36. SCHMIDT WK: Alvimopan (ADL 8-2698) is a novel peripheral opioid antagonist. Am. J. Surg. (2001) 182:S27-S38.
37. ZIMMERMAN DM, GIDDA JS, CANTRELL BE et al.: Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J. Med. Chem. (1994) 37:2262-2265.
38. ZIMMERMAN DM, GIDDA JS, CANTRELL BE et al.: LY246736 dihydrate. Drugs Future (1994) 19:1078-1083.
39. BEATTIE DT, CHERUVU M, MAI N et al.: The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone. Naunyn Schmiedebergs Arch. Pharmacol. (2007) 375:205-220.
40. DELANEY CP, WOLFF BG, VISCUSI ER et al.: Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of Phase III studies. Ann. Surg. (2007) 245:355-63. • This paper in a ideal for a reader interested in a detailed review of the clinical data for alvimopan.
41. TAN EK, CORNISH J, DARZI AW, TEKKIS PP: Meta-analysis: alvimopan vs. placebo in the treatment of post-operative ileus. Aliment. Pharmacol. Ther. (2007) 25:47-57. • This paper in a ideal for a reader interested in a detailed review of the clinical data for alvimopan.
42. KOJIMA M, HOSODA H, DATE Y et al.: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature (1999) 402:656-660. •• This paper describes the first work on ghrelin - a pivotal paper.
43. DATE Y, KOJIMA M, HOSODA H, SAWAGUCHI A et al.: Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology (2000) 141:4255-4261.
44. KOJIMA M, KANGAWA K: Ghrelin: structure and function. Physiol. Rev. (2005) 85:495-522. •• This review updates the reader on the ghrelin story.
45. TAKAYA K, ARIYASU H, KANAMOTO N et al.: Ghrelin strongly stimulates growth hormone (GH) release in humans. J. Clin. Endocinol. Metab. (2000) 85:4909-4911.
46. WREN AM, SEAL LJ, COHEN MA et al.: Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. (2001) 86:5992.
47. PEETERS TL: Ghrelin A new player in the control of gastrointestinal functions. Gut (2006) 54:1638-1649. •• This review, from an expert in the GI field, updates the reader on the ghrelin story.
48. DASS NB, MUNONYARA M, BASSIL AK et al.: Growth hormone secretagogue receptors in rat and human gastrointestinal tract and the effects of ghrelin. Neuroscience (2003) 120:443-453.
49. BASSIL AK, DASS NB, MURRAY CD et al.: Prokineticin-2, motilin, ghrelin and metoclopramide: prokinetic utility in mouse stomach and colon. Eur. J. Pharmacol. (2005) 524:138-144.
50. KITAZAWA T, DE SMET B, VERBEKE K et al.: Gastric motor effects of peptide and non-peptide ghrelin agonists in mice in vivo and in vitro. Gut (2005) 54:1078-1084.
51. ASAKAWA A, INUI A, KAGA T et al.: Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology (2001) 120:337-345.
52. FUJINO K, INUI A, ASAKAWA A et al.: Ghrelin induces fasted motor activity of the gastrointestinal tract in conscious fed rats. J. Physiol. (2003) 550:227-240.
53. BASSIL AK, DASS NB, SANGER GJ: The prokinetic-like activity of ghrelin in rat isolated stomach is mediated via cholinergic and tachykinergic motor neurones. Eur. J. Pharmacol. (2006) 544:146-152.
54. DATE Y, MURAKAMI N, TOSHINAI K et al.: The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology (2002) 123:1120-1128.
55. SAKATA I, YAMAZAKI M, INOUE K et al.: Growth hormone secretagogue receptor expression in the cells of the stomach-projected afferent nerve in the rat nodose ganglion. Neurosci. Lett. (2003) 342:183-186.
56. EDHOLM T, LEVIN F, HELLSTROM PM, SCHMIDT PT: Ghrelin stimulates motility in the small intestine of rats through intrinsic cholinergic neurons. Regul. Pept. (2004) 121:25-30.
57. XU L, DEPOORTERE I, TOMASETTO C et al.: Evidence for the presence of motilin, ghrelin, and the motilin and ghrelin receptor in neurons of the myenteric plexus. Regul. Pept. (2005) 124:119-125.
58. TEBBE JJ, TEBBE CG, MRONGA S et al.: Central neuropeptide Y receptors are involved in 3rd ventricular ghrelin induced alteration of colonic transit time in conscious fed rats. BMC Gastroenterol. (2005) 5:5.
59. SHIMIZU Y, CHANG EC, SHAFTON AD et al.: Evidence that stimulation of ghrelin receptors in the spinal cord initiates propulsive activity in the colon of the rat. J. Physiol. (2006) 576:329-338.
60. FOTIADIS RJ, BADVIE S, WESTEN MD, ALLEN-MERSH TG: Epidural analgesia in gastrointestinal surgery. Br. J. Surg. (2004) 91:828-841.
61. KONTUREK PC, BRZOZOWSKI T, PAJDO R et al.: Ghrelin - a new gastroprotective factor in gastric mucosa. J. Physiol. Pharmacol. (2004) 55:325-336.
62. TRUDEL L, TOMASETTO C, RIO MC et al.: Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. Am. J. Physiol. (2002) 282:G948-G952.
63. DE WINTER BY, DE MAN JG, SEERDEN TC et al.: Effect of ghrelin and growth hormone-releasing peptide 6 on septic ileus in mice. Neurogastroenterol. Motil. (2004) 16:439-446.
64. LIU YL, MALIK NM, SANGER GJ, ANDREWS PLR: Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents. Cancer Chemother. Pharmacol. (2006) 58:326-333.
65. LEVIN F, EDHOLM T, SCHMIDT PT et al.: Ghrelin stimulates gastric emptying and hunger in normal weight humans. J. Clin. Endocrin. Metab. (2006) 91:3296-3302.
66. TACK J, DEPOORTERE I, BISSCHOPS R et al.: Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment. Pharmacol. Ther. (2005) 22:847-853.
67. MURRAY CD, MARTIN NM, PATTERSON M et al.: Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut (2005) 54:1693-1698.
68. BINN M, ALBERT C, GOUGEON A et al.: Ghrelin gastrokinetic action in patients with neurogenic gastroparesis. Peptides (2006) 27:1603-1606.
69. POITRAS P, POLVINO WJ, ROCHELEAU B: Gastrokinetic effect of ghrelin analog RC-1139 in the rat. Effect on post-operative and on morphine induced ileus. Peptides (2005) 26:1598-1601.
70. FRASER GL, HOVEYDA HR, VENKOVA K et al.: Pharmacological separation of gastrointestinal and endocrine effects of ghrelin using a novel ghrelin agonist, TZP-101. Neurogastroenterol. Motil. (2005) 17:85.
71. VENKOVA K, FRASER G HAMID R et al.: Prokinetic effects of a new ghrelin receptor agonist TZP-101 in a rat model of post-operative ileus. Dig. Dis. Sci. (2007) (In Press). • This paper describes pivotal preclinical data on this new compound for POI.
72. TOULOUSE M, FIORAMONTI J, MAGGI C, BUENO L: Role of NK2 receptor in gastric barosensitivity and in experimental ileus in rats. Neurogastroenterol. Motil. (2001) 13:45-53.
73. LECCI A, CAPRIATI A, MAGGI CA: Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome. Br. J. Pharmacol. (2004) 141:1249-1263.